Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2018-11-21T16:30:51Z | - |
dc.date.available | 2018-11-21T16:30:51Z | - |
dc.date.issued | 2018 | * |
dc.identifier.issn | 0923-7534 | * |
dc.identifier.other | OAK-22012 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/246881 | - |
dc.description.abstract | Background: In stage I/II natural killer (NK)/T-cell lymphoma, concurrent chemoradiotherapy (CCRT) had previously been shown to result in superior outcome compared with anthracycline-containing regimens, which have since been considered ineffective. The role of CCRT in comparison with approaches employing nonanthracycline-containing chemotherapy (CT) and sequential radiotherapy (RT) in such patients remains to be defined. Patients and methods: Three hundred and three untreated patients (207 men, 96 women; median age: 51, 18-86 years) with stage I/II NK/T-cell lymphoma who had received nonanthracycline-containing regimens were collected from an international consortium and retrospectively analyzed. Treatment included single modality (CT and RT), sequential modalities (CT+RT; RT+CT) and concurrent modalities (CCRT; CCRT+CT). The impact of clinicopathologic parameters and types of treatment on complete response (CR) rate, progression-free-survival (PFS) and overall-survival (OS) was evaluated. Results: For CR, stage (P=0.027), prognostic index for NK/T-cell lymphoma (PINK) (P=0.026) and types of initial treatment (P=0.011) were significant prognostic factors on multivariate analysis. On Cox regression analysis, ECOG performance score (P=0.021) and PINK-EBV DNA (PINK-E) (P=0.002) significantly impacted on PFS; whereas ECOG performance score (P=0.008) and stage (P<0.001) significantly impacted on OS. For comparing CCRT6CT and sequential CT+RT, CCRT6CT patients (n=190) were similar to sequential CT+RT patients (n=54) in all evaluated clinicopathologic parameters except two significantly superior features (higher proportion of undetectable circulating EBV DNA on diagnosis and lower PINK-E scores). Despite more favorable pre-treatment characteristics, CCRT6CT patients had CR rate, PFS and OS comparable with sequential CT+RT patients on multivariate and Cox regression analyses. Conclusions: In stage I/II NK/T-cell lymphomas, when effective chemotherapeutic regimens were used, CCRT and sequential CT+RT gave similar outcome. © The Author 2017. | * |
dc.language | English | * |
dc.publisher | Oxford University Press | * |
dc.subject | Concurrent chemoradiotherapy | * |
dc.subject | Sequential chemotherapy and radiotherapy | * |
dc.subject | Stage I/II NK/T-cell lymphomas | * |
dc.title | Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 29 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 256 | * |
dc.relation.lastpage | 263 | * |
dc.relation.journaltitle | Annals of Oncology | * |
dc.identifier.doi | 10.1093/annonc/mdx684 | * |
dc.identifier.wosid | WOS:000423741500038 | * |
dc.identifier.scopusid | 2-s2.0-85041196676 | * |
dc.author.google | Kwong Y.L. | * |
dc.author.google | Kim S.J. | * |
dc.author.google | Tse E. | * |
dc.author.google | Oh S.Y. | * |
dc.author.google | Kwak J.Y. | * |
dc.author.google | Eom H.S. | * |
dc.author.google | Do Y.R. | * |
dc.author.google | Mun Y.C. | * |
dc.author.google | Lee S.R. | * |
dc.author.google | Shin H.J. | * |
dc.author.google | Suh C. | * |
dc.author.google | Chuang S.S. | * |
dc.author.google | Lee Y.S. | * |
dc.author.google | Lim S.T. | * |
dc.author.google | Izutsu K. | * |
dc.author.google | Suzuki R. | * |
dc.author.google | Relander T. | * |
dc.author.google | d'Amore F. | * |
dc.author.google | Schmitz N. | * |
dc.author.google | Jaccard A. | * |
dc.author.google | Kim W.S. | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |